Chronic Myeloid Leukaemia
The pre-treatment transcript level of t(9;22) [BCR-ABL] can
inform prognosis and determine downstream log reduction levels.
In addition, three monthly follow up MRD analysis is recommended
as per national and international guidelines.
Studies have indicated PB monitoring for most follow up
time-points is sufficient, with BM monitoring at stipulated time
points, according to national and ELN guidelines, where these will
help to inform when cytogenetics testing is necessary.
The use of donor lymphocyte infusion (DLI) can be indicated in
post-transplant patients. Therefore if DLI is being used, a
clinically urgent test request can be made, so that a shorter
turnaround time is implemented in the laboratory to support
therapeutic decision making. This would also be available when
other clinical urgencies require this, such as loss of a response
or disease progression.